Substitute for form 1449A/PTO Complete if Known **Application Number** Unassigned INFORMATION DISCLOSURE Filing Date Herewith STATEMENT BY APPLICANT First Named Inventor Karimisetty, Srikanth **Art Unit** Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned 2 Sheet of **Attorney Docket Number** 021756-002000US

			U.S. PATENT DO	CUMENTS+	
		Document Number			
Examiner Cite No. 1		Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/NP/	AA	US-6,456,955 B1	09-24-2002	Andrews et al.	
L	AB	US-6,584,459 B1	06-24-2003	Chang et al.	
	AC	US-2002-0023083 A1	02-21-2002	Durkalski	
	AD	US-2002-0107652 A1	08-08-2002	Andrews et al.	
	AE	US-2002-0143726 A1	10-03-2002	Planalp et al.	
VZ	AF	US-2003-0069795 A1	04-10-2003	Boyd et al.	
W	AG	US-2003-0069894 A1	04-10-2003	Cotter et al.	
/NP/	AH	US-2003-0088776 A1	05-08-2003	Lin et al.	
	ļ				
	ļ				
	ļ				
				,	

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document		Dublication Detail	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.¹	Country Code ³	Number ⁴	Kind Code ⁸ (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	⊤ ⁵
		<u> </u>						
·								†

Examiner		Date	20/07/00
Signature	/Nirav Patel/	Considered	06/07/2007

Substitute for form 1449B/PTO				C mpl te if Known		
INIEO	DRAATIC	או הוכ	CLOCUBE	Application Number	Unassigned	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	Herewith	
SIAI				First Named Inventor	Karimisetty, Srikanth	
				Art Unit	Unassigned	
((use as many sheets as necessary)		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	021756-002000US	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ite			
/NP/	Al	*FDA 21 CFR Part 11,* Document Resources, http://www.documentresources.com/document/21cfrpart11.html, pp. 1-2, printed June 23, 2003.			
/NP/	A)	"The Role of Technology Solutions in the Pharmaceutical and Biotechnology Industries' Search for 21 CFR Part 11 Compliance," Life Science CIO Forum, www.lifesciencesCIOforum.com, pp. 1-7 (2002).			
/NP/	AK	*21CFR Part 11 Opportunity or Challenge? With an Analysis of Oracle's OPM,* Life Science CIO Forum, www.lifesciencesClOforum.com, pp. 1-14 (2002).			
			1		

			1		

	,		
Examiner	/Nirav Patel/	Date	06/07/2007
Signature	Titlav Laton	Considered	00/01/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.